Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.93 |
| ▸ | EYA2 | O00167 | 1/20 | 0.93 |
| ▸ | APP | P05067 | 1/20 | 0.93 |
| ▸ | ACE | P12821 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 2/20 | 0.88 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.88 |
| ▸ | TSHR | P16473 | 2/20 | 0.88 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.88 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.88 |
| ▸ | LMNA | P02545 | 1/20 | 0.88 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.88 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.88 |
| ▸ | DRD1 | P21728 | 1/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.88 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.88 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.88 |
| ▸ | DRD3 | P35462 | 1/20 | 0.88 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.88 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL6249529 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL1396907 | 1.00 | TDP1 (0.93) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL1033235 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL4355076 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL28414011 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL7074848 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8090019 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8381723 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL10891778 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL28636599 | 0.97 | TDP1 (0.88) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024104922-A1 | METHOD OF IMPROVING SKELETAL MUSCLE FUNCTION | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023227505-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF CNP COMPOUNDS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023110758-A1 | EFFECTIVE DOSES OF CNP CONJUGATES | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2023-06-22 | — | — | WO | disclosed |
| US-20220118053-A1 | Dry Pharmaceutical Formulations of CNP Conjugates | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-04-21 | — | — | US | disclosed |
| EP-3923906-A1 | DRY PHARMACEUTICAL FORMULATIONS OF CNP CONJUGATES | Ascendis Pharma Growth Disorders A/S (DK) | 2021-12-22 | — | — | EP | disclosed |
| EP-3923905-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF PTH CONJUGATES | Ascendis Pharma Bone Diseases A/S (DK) | 2021-12-22 | — | — | EP | disclosed |
| CN-113423384-A | Dry pharmaceutical formulations of CNP conjugates | 阿森迪斯药物生长障碍股份有限公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-113423383-A | Liquid pharmaceutical formulations of PTH conjugates | 阿森迪斯药物骨疾病股份有限公司 | 2021-09-21 | — | — | CN | disclosed |
| WO-2020165081-A1 | DRY PHARMACEUTICAL FORMULATIONS OF CNP CONJUGATES | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020165087-A1 | LIQUID PHARMACEUTICAL FORMULATIONS OF PTH CONJUGATES | ASCENDIS PHARMA BONE DISEASES A/S (DK) | 2020-08-20 | — | — | WO | disclosed |
| WO-1992013509-A1 | TREATMENT OF ATHEROSCLEROSIS | RUBIN MARTIN (US) | 1992-08-20 | — | — | WO | disclosed |
| US-5114974-A | Magnesium disodium ethylenediaminetetraacetic acid for lowering the iron and calcium in plasma and increasing the magnesium uptake | RUBIN MARTIN (US) | 1992-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220118053-A1 | Dry Pharmaceutical Formulations of CNP Conjugates | CNP, PTMS, NPPA | TDP1 1609/4885EYA2 2261/4885APP 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.